blenrep gsk fda - Search News

News

GSK Shares Drop

The Wall Street Journal on MSN · 1d

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.

GlobalData on MSN · 23h

GSK’s Blenrep faces setback as FDA cancer committee votes against approval

Oncologic Drugs Advisory Committee (ODAC) has voted against the benefit/risk profile of GSK’s Blenrep (belantamab mafodotin) ju

Bloomberg on MSN · 1d

GSK Blood Cancer Drug Blenrep Fails to Win FDA Panel Support

GSK Plc’s blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting its approval in doubt.

Fierce Pharma1d

FDA advisors spurn GSK's Blenrep comeback dreams on safety, trial concerns

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

GlobalData on MSN3d

GSK’s Blenrep US comeback hindered by eye safety concerns

FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

Fierce Pharma4d

As GSK eyes Blenrep's US return, FDA flags eye safety concerns ahead of advisory committee meeting

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results